CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced that the Company will be participating in the William Blair Biotech Focus Conference, taking place July 13, 2022, in New York City. Caraway’s Chief Executive Officer, Martin D. Williams, will participate in a fireside chat with Myles Minter, PhD, Biotech Equity Research Analyst at William Blair, to discuss recent advances in the Company’s lead program targeting the lysosomal cation channel, TRPML1, for the treatment of GBA-Parkinson’s disease (GBA-PD) and other rare genetic diseases.
“We have demonstrated that enhancing TRPML1 function boosts lysosomal function, enhances key lipid recycling pathways that are compromised in GBA-PD patients, and speeds up the clearance of toxic materials that accumulate in a number of genetically defined diseases,” said Williams. “I look forward to speaking with Myles about updates to our TRPML1 program, as well as engaging with investors at the William Blair conference.”
About Caraway Therapeutics
Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The Company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating lysosomal function. Caraway is utilizing its unique product engine to develop proprietary insights into lysosomal function and small molecule ion channel modulation and advance a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The Company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments, and Eisai Innovation.
Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.
